BIOPHYTIS S.A. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.85 EUR | 0.00% |
|
+1.19% | -58.33% |
| 14/05 | Biophytis unveils design for obesity study | CF |
| 14/05 | Biophytis SA Announces the Design of its Phase 2 OBA Clinical Study in Obesity | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Biophytis S.A. is a biotechnology company in the clinical stage specialized in the development of drug candidates to slow degenerative processes and improve functional capacity in patients with age-related diseases, including respiratory failure in patients suffering from COVID-19.
The company is located in Paris, France and Cambridge, Massachusetts.
Calendar
29/10/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -58.33% | 2.41M | |
| +7.52% | 111B | |
| +11.38% | 106B | |
| -12.64% | 22.24B | |
| +0.44% | 21.25B | |
| -4.18% | 18.97B | |
| -37.85% | 18.52B | |
| -8.58% | 16.81B | |
| +37.41% | 12.54B | |
| -23.95% | 8.09B |
- Stock Market
- Equities
- ALBPS Stock
- ALBPS Stock
- News Biophytis S.A.
- European Equities Traded as American Depositary Receipts Down Fall